Rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, belimumab, an inhibitor of B-cell activating factor (BAFF), and eltrombopag, an oral TPO-RA, have each demonstrated clinical benefit in small observational studies [4,7]. This evidence concerns the gene TNFSF13B and rheumatoid arthritis.